GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188191 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Dominika Myśliwczyk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdańsk, 80-210 Gdańsk, Poland. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Pediatric Obesity, Receptors, Gastrointestinal Hormone, Gastric Inhibitory Polypeptide. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pediatric obesity is a chronic, multifactorial neuroendocrine disease in which disrupted gut–brain signaling, hypothalamic appetite regulation, adipose tissue dysfunction, and altered inter-organ communication sustain positive energy balance. Incretin-based therapies translate this biology into mechanism-based treatment, yet their developmental implications remain incompletely defined. This narrative review integrates evidence on GLP-1 and GIP receptor signaling with pediatric trial data and clinical implementation, with particular attention to developmental modifiers of gut–brain signaling and treatment during growth and puberty. We describe how GLP-1 receptor agonists act across central and peripheral tissues to reduce appetite, delay gastric emptying, and enhance glucose-dependent insulin secretion and examine the rationale for dual GIP/GLP-1 receptor agonism. Randomized pediatric trials demonstrate clinically meaningful BMI reduction with liraglutide and semaglutide, with the largest mean effect reported for semaglutide in adolescents; however, long-term effects on growth, puberty, bone health, body composition, and weight maintenance remain uncertain. Tirzepatide has shown greater weight-loss efficacy than selective GLP-1 receptor agonism in adults, but no randomized trial has evaluated it in pediatric obesity without diabetes. Incretin-based therapies should be integrated with nutritional, behavioral, psychological, and family-based care. Their future value will depend on durable efficacy, developmental safety, equitable access, and identification of patients most likely to benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
- Department of Pulmonology, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland.
- Outpatient Cystic Fibrosis Clinic, Department of Pulmonology, Bialystok Medical University Children's Hospital, 15-274 Białystok, Poland.
- Division of Allergology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
ORCID-Profile: Alina Minarowska, Eliza Wasilewska
Zitieren
APA
Myśliwczyk, D., Myśliwiec, M., Minarowska, A., & Wasilewska, E. (2026). GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188191
Vancouver
Myśliwczyk D, Myśliwiec M, Minarowska A, Wasilewska E. GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188191
BibTeX
@article{Myliwczyk2026,
author = {Myśliwczyk, Dominika and Myśliwiec, Małgorzata and Minarowska, Alina and Wasilewska, Eliza},
title = {GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188191}
}
EUVIMED